Biogen Idec, Inc. (Massachusetts) Profit Drops on MS Drug Acquisition
Reuters -- Biogen Idec Inc said on Thursday its second-quarter net earnings fell following the acquisition of rights outside the United States to the experimental multiple sclerosis drug Fampridine-SR.